Pharmaceutical Commerce - December 2022 Issue (PDF)

Trump anticipates that the executive order will help lower drug prices by 30% to 80%.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.